Naturally Occurring Surface Antigen Variants of Hepatitis B Virus in Tunisian Patients

Houda Chaouch^{a, c} Stefania Taffon^d Umbertina Villano^d Michele Equestre^e
Roberto Bruni^d Manel Belhadj^b Naila Hannachi^b Mahjoub Aouni^c
Amel Letaief^a Anna Rita Ciccaglione^d

^aDepartment of Infectious Diseases, Viral Hepatitis Research Unit (UR12SP35), and ^bLaboratory of Microbiology-Immunology, UR02SP13, University Hospital Farhat Hached, Sousse, and ^cLaboratory of Infectious Diseases and Biological Agents, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia; ^dViral Hepatitis Unit, Department of Infectious, Parasitic and Immune-Mediated Diseases, and ^eDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Key Words

Hepatitis B surface antigen mutation · Hepatitis B surface antigen subtype · Major hydrophilic region · Tunisia

Abstract

In Tunisia, the prevalence of naturally occurring surface (S) gene variants of hepatitis B virus (HBV) has not been determined. In the present study, the prevalence of these variants was examined in terms of the clinical and viral state in a series of 99 Tunisian patients with HBV infection. The S genes were amplified and directly sequenced. Genotype D was predominant (98%), 40.4% isolates belonged to subgenotypes D7 and 1 to subgenotype D2. The most common subtype was ayw2 (95.9%). In total, 60.6% of the studied strains harbored S mutations. Several novel mutation patterns were detected. Interestingly, the presence of S mutations was significantly correlated with the D7 subgenotype, low HBV DNA and advancing age (≥ 35 years), and tended to be higher in liver cirrhosis than in chronic infection. The global prevalence of the major hydrophilic region variants was 12.1%,

with substitution S143L/T as the most frequent (4%). Only 33.9% of S substitutions produced amino acid changes in the polymerase gene. In conclusion, a high prevalence of naturally occurring HBsAg variants was observed among Tunisian HBV carriers. Natural viral variability in a geographical region and duration of infection are among the major factors associated with the occurrence of S mutations.

© 2016 S. Karger AG, Basel

Introduction

Despite the availability of hepatitis B surface antigen (HBsAg) vaccines and mass immunization schemes, hepatitis B virus (HBV) infection continues to be a major public health problem with more than 350 million chronically infected people, some of whom develop liver cirrhosis and hepatocellular carcinoma [1].

HBV is an enveloped virus belonging to the Hepadnaviridae family. The genome is a small circular partially double-stranded DNA molecule of about 3.2 kb, in-

cluding 4 overlapping open reading frames (ORF). HBV displays remarkable genetic diversity, compared to other DNA viruses, related to high levels of virus production and error-prone nature of the reverse transcriptase (RT) polymerase. In addition, host immune systems, passive and active immunization, and antiviral therapy act as selective pressures driving HBV evolution [2]. To date, molecular phylogenetic analyses of HBV have revealed 9 genotypes (A–I) and approximately 40 subgenotypes which exhibit different geographical distribution [3].

HBsAg, the major envelope protein of HBV, is composed of 226 amino acids (aa) and contains a central region called the major hydrophilic region (MHR) from aa 100 to 169, which is highly immunogenic and is under selective pressure of the immune system. Interestingly, the MHR contains a cluster of major B-cell epitopes located between aa 124 and 147, termed the ‘a’ determinant. This highly conserved region is considered the major immune target for antibodies induced by passive or active immunization and used in diagnostic assays [4]. Mutation of HBsAg, particularly within the ‘a’ determinant, could alter the antigenicity of this protein, leading to neutralization failure of virus by anti-HBs antibody and may cause escaping from the host’s immune system [5, 6]. These mutations can be selected under immune pressure during the course of HBV infection [7, 8], either within or outside the MHR region [9–11].

Understanding the prevalence and diversity of HBsAg variants is of high importance, because this will affect policy decisions relating to vaccine and diagnostic reagent design [12]. However, the prevalence of S mutations is still unknown in many geographical regions. De Madalena et al. [13] found that genotype D strains carry more mutations in the ‘a’ determinant with potential escape mutants in nonvaccinated subjects. Therefore, they indicate the need for careful surveillance of these variants in areas in which genotype D predominates. Tunisia is a country with an intermediate HBV endemicity; the prevalence of HBsAg ranges from 4 to 7% [14] with predominance of genotype D [15, 16]. However, to date there has been a lack of data on the genetic diversity of HBsAg from HBV isolates circulating in Tunisia. The prevalence of HBsAg polymorphisms is still unknown and should be recorded.

The aim of the present study was to determine the prevalence of naturally occurring HBsAg polymorphisms and describe the specific mutation patterns in a significant number of HBV strains isolated from Tunisian patients.

Materials and Methods

Patient Samples

The study population included 99 HBV chronic carriers selected from patients followed for hepatitis B infection, in the Department of Infectious Diseases at Farhat Hached University Hospital in Sousse, during the period from 2010 to 2014. The diagnosis of HBV infection was based on a positive result of HBsAg for at least 6 months and a positive result for HBV DNA. Exclusion criteria were: coinfection with hepatitis C virus (HCV), hepatitis D virus and human immunodeficiency virus. None of the patients were vaccinated for HBV or had received antiviral or immunoglobulin therapy. The serum samples from all patients were stored at –20°C until analysis. The study was reviewed and approved by the Ethics Committee of Farhat Hached University Hospital.

Serological and HBV DNA Quantitative Assays

Hepatitis B virus markers (HBsAg, anti-HBs, anti-HBc total, HBeAg, anti-HBe) and HCV (anti-HCV) were detected by microparticle enzyme immunoassay technology (AxSYM; Abbott Laboratories, Abbott Park, Ill., USA). Liver function tests, including alanine aminotransferase and aspartate aminotransferase, were measured using commercially available autoanalyzers. HBV DNA levels were quantified by a commercial real-time PCR (COBAS AmpliPrep/COBAS TaqMan, Roche Diagnostics); the detection limit was 12 IU/ml.

Extraction of HBV DNA, Amplification and Sequencing of Surface Gene

Viral DNA was extracted from 200 µl serum using the EZ1 Virus Mini Kit v.2.0 (Qiagen, Hilden, Germany) following the manufacturer’s instructions. HBV DNA was amplified by polymerase chain reaction (PCR), as previously described [17], with the platinum Taq DNA polymerase (Invitrogen, Life Technologies Corporation, Monza, Italy). The PCR products were purified using the Amicon® Ultra-0.5 Centrifugal Filter Devices in accordance with the manufacturer’s instructions. Sequencing reactions were performed using the Genome Lab DTCS Quick Start Kit (Beckman Coulter Inc., Fullerton, Calif., USA) and were run on an automated DNA sequencer (Beckman Coulter Inc.). PCR and sequencing were possible only for serum samples with a viral load above 2,000 IU/ml. A fragment of the S gene, which comprised codons 33–226 of the HBsAg molecule, was selected for analysis.

Sequence and Phylogenetic Analysis

Sequence analysis was performed with Chromas software and BioEdit Package. For the phylogenetic analysis, the 99 sequences obtained in this study were aligned with representative reference sequences of all known HBV genotypes and different subgenotypes of genotypes D (D1–D8) and A (A1–A6) imported from the GenBank database. The sequences were aligned using the ClustalW program incorporated in BioEdit sequence alignment software. Genetic distance was estimated using the Kimura two-parameter model, and the phylogenetic tree was constructed using the neighbor-joining algorithm in the MEGA software. The reliability of the phylogenetic tree was tested by bootstrap analysis with 1,000 replicates. The S gene sequences generated in this work have been deposited in the GenBank database under accession numbers 1TunSO_14 to 102TunSO_14.

Table 1. Characteristics of the patients and HBV isolates with and without S mutations

	All patients (n = 99)	Patients with S mutations (n = 60)	Patients without S mutations (n = 39)	Statistical analysis (OR/p value)
Age ^a , years	36.4±11.1	38.4±11.5	33.4±9.9	p = 0.03*
Age ≥35 years ^b	51 (51.5)	37 (61.6)	14 (35.8)	OR = 2.9, p = 0.01*
Gender (M/F) ^b	52/47	29/31	23/16	OR = 1.5, p = 0.3
HBeAg positive ^b	18 (18.1)	10 (16.6)	8 (20.5)	OR = 0.7, p = 0.6
HBV DNA ^a , IU/ml	10,214 [2,200–10 ⁷]	6,190 [2,200–10 ⁷]	26,000 [2,400–10 ⁷]	p = 0.1
HBV DNA ≤10,000 IU/ml ^b	50 (39.4)	35 (58.3)	15 (38.4)	OR = 2.3, p = 0.04*
ALT ^a , IU/l	55.5±129	58.8±154.1	50.4±80.1	p = 0.7
Cirrhosis ^b	12 (12.1)	9 (15)	3 (7.6)	OR = 2.1, p = 0.2
Genotype				
A	1 (1)	1 (1.6)	0	n.a.
D	97 (98)	58 (96.6)	39 (100)	
Subgenotype ^b				
D7	40 (40.4)	30 (50)	10 (25.6)	OR = 3, p = 0.01*
D2	1 (1)	1 (1.6)	0	
Other	58 (58.6)	29 (48.3)	29 (74.3)	
HBsAg subtype				
ayw2	95 (95.9)	56 (93.3)	39 (100)	n.a.
ayw3	2 (2)	1 (1.6)	1 (2.5)	
adw2	2 (2)	1 (1.6)	1 (2.5)	

Data are presented as means ± SD, numbers with percentages in parentheses, or medians with ranges in square brackets. ALT = Alanine aminotransferase; OR = odds ratio; n.a. = not adopted. * p < 0.05.

^a Statistical significance was calculated using the two independent samples t test.

^b Statistical significance was calculated using the χ^2 test.

Identification of HBV Subtype and Variations of S Gene

The nucleotide sequences of each sample were translated into envelope gene aa sequences according to the ORF of the S gene (S ORF). HBsAg subtype was predicted from the aa sequence of the S gene, by a new algorithm [18], which is based on identifying aa at positions 122, 127, 140, 159, and 160. For identifying HBsAg variants, deduced aa sequences were aligned and compared with the HBV reference sequence of the same genotype in BioEdit software. As the S gene overlaps completely with the polymerase gene, the deduced aa sequence of the corresponding fragment of the polymerase was analyzed, and effects of HBsAg variations on the polymerase protein were determined by translation of the sequences according to the polymerase ORF (P ORF).

Statistical Analysis

Statistical analyses were performed using SPSS software. Values were expressed as percentages, median (ranges) or as mean ± standard deviation when appropriate. Differences between categorical variables were analyzed using Fisher's exact test or the χ^2 test. Student's t test was used for continuous variables. Correlation of S variant occurring with demographic and clinical features was identified by univariate and multivariate analyses using a logistic regression analysis. A p value <0.05 was considered statistically significant.

Results

Patient Characteristics

Ninety-nine patients with chronic HBV infection were studied. The study subjects consisted of 52.5% males (n = 52) and 47.5% females (n = 47) with a mean age of 36.4 years and a range of 19–71 years. Among them, 18.1% were HBeAg positive, and 12.1% had liver cirrhosis. Demographic and virological data of patients are illustrated in table 1.

Identification of HBV Genotypes and Subgenotypes

Phylogenetic analysis showed that genotype D was predominant, accounting for 98 out of 99 isolates (data not shown). Genotype A was found in only 1 sample. Among the 98 genotype D isolates, 41 (41.4%) were successfully subgenotyped by a statistically supported phylogenetic tree (fig. 1). Overall, 40/98 isolates belonged to subgenotype D7 (40.8%) and 1/98 to subgenotype D2 (1%). For the remaining 57 genotype D isolates (58.1%), it was impossible to obtain a statistically supported sub-

Fig. 1. A phylogenetic tree constructed using the neighbor-joining method, showing D2 and D7 subgenotypes from 41 Tunisian HBV patients.

genotyping tree as variation in the sequenced region was not high enough to classify these HBV isolates. Thence, all the analyses were performed considering two large subgenotype groups: the 'D7 subgenotype group', including all 40 D7 isolates, and the 'other subgenotype group', including 57 uncharacterized genotype D isolates. The results are summarized in table 1.

Prediction of HBsAg Subtypes and Association with HBV Genotypes

The majority of Tunisian HBV strains belonged to the aYW2 subtype (95.9%, 95/99) based on Arg122, Lys160, Pro127, Tyr134 and/or Gly159. Whereas adW2, based on Lys 122, Lys160, Pro127, Phe134 and Ala 159, was found in only 2 isolates, 1 genotype D and in the single strain of genotype A. Subtype aYW3, based on Arg122, Lys160 and Thr127, was found in 2 D7 isolates and in the single strain D2. Results concerning HBsAg subtypes are shown in table 1.

Genotype- and subgenotype-dependent polymorphisms and variations at positions 122, 127, 140, 159, and 160 were not considered as MHR mutations.

Mutation Analysis of the S Gene in Tunisian HBV Isolates

Analysis of the 99 HBV Tunisian patients revealed several aa substitutions in the S region that codes aa 33–226. Overall, 346 nucleotide substitutions occurred, of which 115 (33.2%) were missense (aa mutations), and 231 (66.7%) were silent (no aa change). In total 60/99 (60.6%) of the studied strains harbored 115 mutations at 48 different aa positions of HBsAg. Thirty-one (51.6%) of the strains with aa substitutions showed a single mutation, whereas 29 (48.3%) had a combination of 2–7 mutations.

In univariate analysis, the comparison of clinical and virological characteristics between patients with and without S variants revealed that age ≥ 35 years was significantly associated with occurrence of S variants (OR = 2.912, 95% confidence interval, CI = 1.245–6.628; $p = 0.01$; table 1). No significant association with patient sex was detected. In addition, 75% of D7 subgenotype isolates displayed S mutations, thus making the correlation with this subgenotype highly significant (OR = 3.000, 95% CI = 1.242–7.244; $p = 0.01$). The correlation between the presence of S mutations and low HBV DNA level ($\leq 10,000$ IU/ml) was found to be significantly associated (OR = 2.333, 95% CI = 1.019–5.342; $p = 0.04$), whereas the correlation with HBeAg status was not found to be statistically significant ($p = 0.5$). Although the frequency of mutations was higher in cirrhosis patients, the correlation

with cirrhosis did not reach statistical significance ($p = 0.2$).

In multivariate analysis, D7 subgenotype and low HBV DNA ($\leq 10,000$ IU/ml) were found to be significant independent variables associated with the occurrence of S variants (OR = 1.210, 95% CI = 1.039–1.409; $p = 0.01$; and OR = 2.924, 95% CI = 1.224–6.982; $p = 0.01$), respectively.

Allocation of Mutations to Surface Protein Immune Epitopes

The pattern of mutated distribution was established using the published data on the different HBV surface protein immune epitopes [19]. In total, 1, 4 and 4 regions have been proposed for B-cell, T-helper and CTL immune epitopes across the surface protein, respectively. Our results demonstrated that most of the aa substitutions (79.1%, 91 of 115 mutations) occurred in different antigenic epitopes of the S gene, with the following distribution: 14 (12.1%) in B-cell epitopes in 8 residues, 26 (22.6%) in T-helper epitopes CD4+ in 13 residues and 51 (44.3%) inside CTL epitopes in 15 residues; 24 mutations (20.8%) were positioned out of these regions.

MHR Mutational Patterns

Twelve (12.1%) of 99 patients showed an aa substitution in the MHR region. aa substitution in the 'a' determinant region was observed in 8 isolates (8%). Nine isolates displayed only 1 MHR mutation, whereas 3 had a combination of 2 mutations, making the total number of discovered MHR mutations 15. As a result of single base substitution, 9 aa residues were affected: 104, 110, 118, 128, 134, 138, 143, 150, and 169. Interestingly, in 1 HBeAg-positive chronic patient (patient 9094 in table 2), a 24-nucleotide deletion was detected in the MHR, affecting 8 codons: s110–s117. No insertion or stop codons were observed in this region.

The most variable position in the MHR was aa 143 with a rate of 4% (4/99), including Ser143Leu and Ser143Thr, each detected in 2 patients with chronic hepatitis B. This degree of diversity is followed by Y134N/F (3%), L104W (0.99%), I110L (1%), T118V (1%), A128V (1%), C138G (1%), I150V (1%), and R169H (1%). Different frequencies of mutations within the MHR and other regions of HBsAg are illustrated in figure 2a. Interestingly, an alteration of aa cysteine residues of disulfide bonds in the 'a' determinant at position 138 was detected in 1 chronic infection patient (patient 234 in table 2). aa cysteine residues at positions 124, 137, 139, and 147 had no alterations and were considered as conserved positions.

Table 2. Clinical and virological characteristics of 60 patients with aa substitutions in the HBsAg

Patient	Gender, age	HBeAg/anti-HBe	ALT, IU/l	HBV DNA, IU/ml	Genotype/subgenotype/subtype	Clinical status	S mutations	Corresponding RT mutations
27	M, 44	-/+	74	980,302	D7/ayw2	CHB	S204R	K212T
28	M, 47	-/+	42	19,291	D/adw2	CHB	S207R	Y54H*, Q215S
42	M, 29	-/+	32	3,180	D/ayw2	CHB	G44E, S204N	-
50	F, 40	-/+	19	4,050	D7/ayw2	CHB	L42R	Y54H*
59	M, 40	-/+	29	2,680	D7/ayw2	CHB	S143L ^a	-
70	F, 42	-/+	17	2,720	D7/ayw2	CHB	Y206C	S189P*
80	F, 37	-/+	14	3,590	D7/ayw2	CHB	Y206C	Y54H*, N76D*, M129L*, S189P*
81	M, 25	-/+	15	5,628	D/ayw2	CHB	T68I	-
82	F, 36	-/+	13	33,000,000	D7/ayw2	CHB	V224A	-
85	M, 39	-/+	32	10,968	D7/ayw2	CHB	S207N	Y54H*
86	F, 35	-/+	14	5,790	D/ayw2	CHB	T45N	N53K, Y54H*, I187L*
88	M, 28	-/+	54	42,000	D7/ayw2	CHB	Y36R, C76Y, L213I	V44E, F221Y
91	M, 24	-/+	41	3,000	D/ayw2	CHB	S204R	S213T, L91I*, L220I*
97	F, 36	-/+	30	2,640	D7/ayw2	CHB	L175S, 216STOP	Y54H*
107	M, 37	-/+	26	53,900	D7/ayw2	CHB	Q51R, I110L ^a , F212Y	N118T
110	F, 58	-/+	42	4,000	D7/ayw2	CHB	S207N	Y54H*, A38E, S106A*
124	F, 44	-/+	16	4,150	D/ayw2	CHB	S193L, S207P	Q215S, L91 I*
138	M, 39	-/+	23	9,090	D7/ayw2	CHB	S55C, S207I	Q215H
140	M, 33	-/+	12	14,700	D7/ayw2	CHB	P203R	L91I*
144	F, 50	-/+	13	4,890	D/ayw2	CHB	N52S	Y54H*, N76D*
145	M, 38	-/+	14	4,800	D7/ayw2	CHB	Y206C, S207R	Y54H*, Q215P
147	F, 38	-/+	23	4,100	D7/ayw2	CHB	S207N	L91I*, R120G*
151	F, 32	-/+	17	2,620	D7/ayw2	CHB	S143T ^a , I150V ^a	F151T, Y158C
159	F, 42	-/+	22	3,400	D/ayw2	CHB	L175A, S210R, F219V	H124N*, S219A, F183C, F227C
165	M, 44	-/+	27	245,000	D/ayw2	CHB	T45P, S143T ^a , F170S, I208T, S193A	N53T, Y54H*, F151Y, N118D*, F201C
171	F, 23	-/+	24	4,200	D/ayw2	CHB	L175V, S207N, F219V	Y54H*, F183C, F227C
174	M, 38	-/+	70	4,500	D7/ayw2	CHB	S38T, T189I, V190A, V194A, S207T	F46Y, Q215H, S189P*
178	F, 44	-/+	13	2,720	D7/ayw2	CHB	I208T	N76D*, S189P*
179	F, 25	-/+	24	19,400	D7/ayw2	CHB	S204N	-
185	F, 19	-/+	18	4,960	D7/ayw2	CHB	193STOP, S204R, Y206C	F201L, S213T
223	M, 26	-/+	16	2,810	D/ayw2	CHB	216STOP	-
227	F, 25	+/-	21	20,400	D/ayw2	CHB	L222F	A194S*, S230F
232	F, 43	-/+	18	4,300	D7/ayw2	CHB	S207N	-
234	F, 48	-/+	16	11,300	D/ayw2	CHB	C138G ^a , L175I, 216STOP	L146W, F183Y
238	F, 27	-/+	31	9,060	D7/ayw2	CHB	R169H ^a , 216STOP	A97T*
240	F, 46	-/+	21	21,440	D7/ayw2	CHB	S207N	-
245	M, 53	-/+	28	8,000	D/ayw2	CHB	S204N, S207N, I218M, F219V	Y54H*, F227G
259	M, 19	-/+	21	9,340	D7/ayw2	CHB	S207N	-
263	F, 32	+/-	171	29,499	D7/ayw2	CHB	S207R, V224A	Q215S
269	M, 37	-/+	14	2,719	D/ayw2	CHB	L175I	F183Y
276	M, 20	+/-	80	11.10 ⁷	D/ayw2	CHB	F170S, S193A, L209W	F201C
285	M, 26	-/+	23	3,520	D2/ayw3	CHB	T118V ^a , A128V	H126R, S135Y
298	F, 44	-/+	19	6,190	D7/ayw2	CHB	S207N	-
303	F, 34	-/+	10	6,130	D/ayw2	CHB	F85C	-
336	F, 31	+/-	137	2,780,000	D/ayw2	CHB	S193A	F201C
337	F, 26	-/+	36	1,239,000	D7/ayw2	CHB	R79H	-
363	F, 26	+/-	42	170,000,000	D7/ayw2	CHB	Y225S	-
369	M, 52	-/+	55	2,200	A/adw2	CHB	N40S, S45P, A194V, I213L	I53T, Y221F, N248H*

Table 2 (continued)

Patient	Gender, age	HBeAg/anti-HBe	ALT, IU/l	HBV DNA, IU/ml	Genotype/subgenotype/subtype	Clinical status	S mutations	Corresponding RT mutations
375	M, 32	+/-	62	11.10 ⁷	D7/ayw2	CHB	C76Y, S207R	Q215S
379	F, 29	+/-	97	170,000,000	D/ayw2	CHB	S143L ^a	-
9,094	F, 40	+/-	24	110,000,000	-/ayw2	CHB	deletion 110-117 ^a	deletion 119-126
87	F, 71	-/+	160	148,000	D7/ayw2	LC	S210R	A97T*, S219A
353	M, 41	+/-	1,200	39,500,000	D/ayw2	LC	F83C, L91H, L104W ^a , Y134N ^a , L213I	Y54H*, V142E, F221Y
357	F, 51	-/+	145	170,000,000	D/ayw2	LC	I208T, S210R	S219A
20,322	M, 45	-/+	35	2,242	D/ayw2	LC	Q54R, T189I	Y54H*
1,995	M, 41	+/-	79	13,607,924	D/ayw2	LC	L88P, Y134N ^a , F170S	V142E
2,660	F, 45	-/+	68	-	D/ayw2	LC	L49R, Y134F ^a , T189I	N53D*
380	M, 63	-/+	29	2,100	D/ayw2	LC	I208T, L213I	L91I*, F221Y
381	M, 66	-/+	33	3,310	D/ayw2	LC	T45R	N53K*, Y54D
377	M, 61	-/+	27	2,890,000	D/ayw2	LC	L49R, L77R, F80S, F83S, W201S, L213I, 216STOP	Y54H*, L209F, F221Y

ALT = Alanine aminotransferase; CH = chronic hepatitis; LC = liver cirrhosis; * = RT silent mutation in HBsAg.

^a aa substitution in the MHR region.

Fig. 2. Character variation of HBsAg and overlapping RT sequence for the 99 clinical isolates. Frequency and distribution of aa substitutions in the HBsAg (a) and overlapping RT sequence (b). The 99 clinical sequences were plotted in the same graph to identify polymorphic and conserved domains. The horizontal axis indicates the

aa position of encoded HBsAg protein (aa 33–226) and RT (42–232). The MHR and 'a' determinant domain are represented for HBsAg; A, B and C domains are represented for RT. The vertical axis indicates the frequency of aa variation at each aa position.

Table 3. Biochemical characterization of aa within the MHR and their clinical importance in wild-type and mutant variants

Position at the MHR	Wild-type aa	Mutant aa	Affects serological diagnosis	Vaccine escape mutant	Failure in HBIG therapy	References
104	<i>Leu</i>	<i>Trp</i>	–	–	–	This study
110	<i>Ile</i>	<i>Leu</i>	Yes	n.d.	n.d.	Katsoulidou et al. [64], 2009
118	Thr	<i>Val</i>	–	–	–	This study
128	<i>Ala</i>	<i>Val</i>	Yes	n.d.	n.d.	Katsoulidou et al. [64], 2009
134	Tyr	<i>Phe</i>	Yes	Yes	Yes	Katsoulidou et al. [64], 2009
	Tyr	Asn	Yes	n.d.	n.d.	Avellon and Echevarria [30], 2006
138	Cys	<i>Gly</i>	–	–	–	This study
143	Ser	Thr	Yes	n.d.	n.d.	Katsoulidou et al. [64], 2009
	Ser	<i>Leu</i>	yes	Yes	n.d.	Avellon and Echevarria [30], 2006
150	<i>Ile</i>	<i>Val</i>	–	–	–	This study
169	<u>Arg</u>	<u>His</u>	n.d.	n.d.	n.d.	Pourkarim et al. [65], 2014

Basic aa are underlined, hydrophobic aa are in italics, and hydrophilic aa are in bold. n.d. = Not determined.

The biochemical characterizations of aa in wild types and mutants in the MHR, along with their known functional effects, are illustrated in table 3. The variants involved in a failure of HBsAg detection were found in samples of 7 patients (7%, 7/99). The variants associated with vaccine escape were detected in samples of 2 patients (2%, 2/99), whereas variants involved in immunotherapy escape were detected in 1 patient (1%, 1/99).

No significant correlation was found between mutations in the MHR and other clinical and virological characteristics, including age ($p = 0.7$), sex ($p = 0.8$), alanine aminotransferase level ($p = 0.3$), HBeAg status ($p = 0.2$), cirrhosis ($p = 0.1$), genotype ($p = 1$), and HBV DNA levels ($p = 0.5$) (data not shown).

aa Mutations Outside the MHR

This analysis revealed several aa substitutions outside the MHR region. In total 100 (86.9%) of the 115 detected S mutations occurred outside the MHR. Forty-nine isolates displayed only mutation outside the MHR, whereas 7 had a combination of mutations outside and inside the MHR, making the total number of patients with outside MHR mutations 56 (56.5%). As a result of single base substitution, 41 different aa positions outside the MHR were affected (fig. 2a), the most variable position was aa 207, for which mutations were present in 16 out of 99 strains (16.1%). Six stop codons were found upstream of the MHR, 5 in position 216 and 1 at position 193 (results do not correlate with either biochemistry or serology status of the patients). No insertion or deletion was observed in these regions.

Of the 115 aa substitutions in the S gene, 39 (33.9%) produced aa changes in the polymerase gene (table 1). In addition, 60 RT silent mutations in HBsAg were found; none caused substitution on the S protein. No change was observed in the YMDD motif. Substitution rtQ215S/P/H corresponding to sS207R/P/I, discovered in 7 strains, was the only provided antiviral resistance-associated mutation detected. B and C domains of the RT present very few polymorphisms, despite aa variability of overlapping HBsAg frame (fig. 2b).

Discussion

Phylogenetic analysis showed the predominance of genotype D in the Tunisian population which was detected in 98% of cases. This result is in accordance with previous studies showing a predominance of genotype D in Tunisia [15, 16] and in the Mediterranean region [3]. Isolates from 41 of the 99 patients (41.4%) were successfully subgenotyped. Overall, 40 isolates belonged to subgenotypes D7 (40.4%) and 1 to subgenotype D2 (1%). Subgenotype D7 was recently described and found prevalent in Tunisia and in Morocco [16, 20], suggesting to be the most predominant in the Maghreb. This hypothesis is reinforced by the results of our study. Interestingly, this study was the first that describes the HBsAg subtype prevalence in Tunisia. Subtype ayw2 was the most predominant (95.9%), and the dominance of genotype D was associated with subtype ayw2, and few cases were associated with ayw3 and adw2. This result is in agreement with oth-

er studies which reported the predominance of subtype ayw2 in Mediterranean countries [20, 21].

Analysis of the 99 HBV Tunisian patients revealed several substitutions in the S region that codes aa 33–226. The global prevalence of naturally occurring HBsAg variants was high (60.6%) and indicated that HBV circulating in Tunisia could exhibit a significant proportion of S mutations. Prevalence of S mutants from most geographical regions is unknown; in fact, the majority of studies focused on variations in the MHR region.

The demographic and clinical characteristics of patients indicate a significant association between the occurrence of HBsAg variants and advancing age (≥ 35 years), irrespective of the clinical groups of patients or HBV subgenotypes. Considering the mean age of the study subjects (36 years), most of the patients were born before the national HBV vaccination program for neonates had started in 1995. Thus, it is hypothesized that most of the subjects acquire their HBV infection in the perinatal period or infancy and the duration of HBV infection is assumed to approximate their age. This could explain that older age is more associated with a longer history of HBV infection, suggesting that most variants emerge with long-term HBV disease duration host immune selective pressure.

HBsAg mutations were correlated with genotype D. This fact is explained not only by the domination of this genotype in our study, but also by its established higher variability. De Maddalena et al. [13] reported a significantly higher intragenotypic distance in genotype D than genotypes A and G, especially at the 'a' determinant. Thus, it can be suggested that what is already known about the higher affinity of genotype D for mutations in the pre-C region can also be true for other regions [22, 23]. This hypothesis is reinforced by the results of our study. Interestingly, HBsAg mutations were correlated with subgenotype D7 in present data.

Naturally occurring MHR variants were 12.1%. Nucleotide sequence variations in the MHR, the highly antigenic segment of HBsAg, may have important clinical features such as diagnostic problems and escape from immune recognition [24]. Thus, the prevalence and types of MHR variants are of interest. The up-to-date published data for several countries show notable differences: from 14.8% in Argentina [25], 15% in Morocco [20], 17.2% in Iran [26], 24% in Japan [27], 27.2% in Turkey [21], 27.8% in France [28], 28% in Taiwan [29], up to 39% of unselected chronic carriers in Spain [30], 46.5% in Korea [31], and 46.6% in China [32]. This variability of results about MHR substitution prevalence may be attrib-

uted to differences in the genetic factors [33, 34] and to characteristics of populations studied. Indeed, it has been suggested that age, advanced liver disease, HBeAg-negative status, and antiviral therapy influence the occurrence of MHR mutations [35–38]. Moreover, it is essential to note that 8% of patients had mutations in the 'a' determinant of the MHR. Higher mutation frequencies of MHR variants (60%) were observed inside the 'a' determinant, which confirm the finding of previous studies [27, 39, 40].

A large number of MHR mutants that have been previously reported to be in association with failure of HBsAg detection were detected in this study (table 3). Ser143Leu/Thr was the most common MHR variation of the studied population; this substitution is known to cause incongruity in some diagnostic assays [41, 42]. Ser143Leu was also detected in the follow-up plasma samples, suggesting that it was a stable variant [21].

In the present study, variants associated with vaccine and immunotherapy escape were found in 2 and 1% of carriers, respectively. A potential problem of patients with high viral load carrying MHR variations is the possibility of becoming the source of transmission, especially variants which could escape from vaccine-induced antibodies [38, 43]. Thus, the great danger of vaccine escape mutants is their emergence in the general population including HBV-vaccinated individuals [44]. One of the most frequent and well-documented vaccine escape mutants is G145R [45, 46]; HBV isolates with G145R are known to be transmitted despite vaccination against HBV [47]. In our study, none of the patients displayed substitution G145A. However, the presence of other immune escape mutants in our population should be considered in the immunization program.

Mutation C138G associated with cysteine residues was observed in 1 patient. To our knowledge, C138G has not been previously reported. The loss of cysteine residues was notable, because this could lead to a dramatic change in the conformation of MHR and in its antigenicity [41, 48]. Interestingly, we reported a novel 24-nucleotide deletion which affected 8 aa of HBsAg from aa 110 to aa 117. Since Yamamoto et al. [49] observed the first insertion in the S gene, insertion/deletion in HBsAg had been reported in various studies [50–53]. To the best of our knowledge, the present study is the first reporting an MHR deletion which affected this number of codons. Insertion or deletion in the MHR may cause the loss of conformational epitope and modify antigenicity of HBsAg, render HBsAg undetectable, or induce immune escape variants to evade virus clearance [52, 54, 55].

Our study showed that the MHR is the more conserved region in the S gene, consistent with previous results showing that most occurrences of S mutations were in the region outside the MHR [22, 40].

In the present data, most of the aa substitutions (79.1%) occurred in different immune epitopes of the S gene. This finding was in agreement with the results of other studies, especially in genotype D-infected patients [22, 56]. In our study group, nearly half of the mutations (44.3%) occurred in the CTL epitope, suggesting a narrowly focused immune selection pressure at a hot spot position.

The role of S mutations in the outcome and persistence of HBV infection remain unclear. Various studies reported a tendency for a higher prevalence of S variants in patients at an advanced stage of liver disease [21, 57–59] and suggest that active viral replication under host immune pressure seems to cause the accumulation of S variations. However, these findings may not be conclusive in this study since the number of cirrhosis patients was small. Some S mutation patterns have been found in association with cirrhosis [60–62]. In the present data, 3 mutations were detected in association with cirrhosis: one is the Y134N mutation, inside the MHR, the others are L49R and L213I mutations, outside the MHR. These mutations might play a pivotal role in the development of cirrhosis.

The polymerase gene was more conserved and not all HBsAg variants were accompanied by substitutions in the polymerase. RT domains appear constrained with only

substitutions corresponding to antiviral resistance. As reported recently, HBV polymerase and surface proteins may evolve independently despite the overlapping of their genes [63].

In conclusion, a significant prevalence of naturally occurring HBsAg variants was observed among Tunisian chronic HBV carriers. Interestingly, some novel variants and mutation patterns were detected. Most of these polymorphisms are not associated with disease immune selection but with disease duration, as we found a clear association with age. Interestingly, we have shown a correlation with subgenotype D7. Based on these results, it can be concluded that natural viral variability in a geographical region and duration of infection are among the major factors associated with occurrence of S mutations. Considering that chronic carriers are the major reservoir of HBV infection, the selection of such variants in these patients could increase the problem of transmission of these variants in the general population. Therefore, their role in the natural course of HBV infection should be clarified, and epidemiological monitoring of naturally occurring HBsAg variants is essential, especially for immunotherapy and vaccination efficacy.

Disclosure Statement

The authors have no conflicts of interest to disclose.

References

- 1 Lok AS: Natural history and control of perinatally acquired hepatitis B virus infection. *Dig Dis* 1992;10:46–52.
- 2 Echevarria JM, Avellon A: Hepatitis B virus genetic diversity. *J Med Virol* 2006;78:36–42.
- 3 Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al: Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes and HBsAg subtypes. *Intervirology* 2004;47:289–309.
- 4 Carman WF: The clinical significance of surface antigen variants of hepatitis B virus. *J Viral Hepat* 1997;4:11–20.
- 5 Cooreman MP, Leroux-Roels G, Paulij WP: Vaccine and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. *J Biomed Sci* 2001;8:237–247.
- 6 Fortuin MKV, Karthigesu V, Allison L, Howard C, Hoare S, Mendy M, et al: Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. *J Infect Dis* 1994;169:1374–1376.
- 7 Ngui SL, O'Connell S, Eglin RP, Heptonstall J, Teo CG: Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. *J Infect Dis* 1997;176:1360–1365.
- 8 Ijaz S, Ferns RB, Tedder RS: A 'first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of 'second loop' immune escape. *J Gen Virol* 2003;84:269–275.
- 9 Mancini-Bourguine M, Fontaine H, Brechot C, Pol S, Michel ML: Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. *Vaccine* 2006;24:4482–4489.
- 10 Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, et al: Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. *J Immunol* 1994;152:3074–3087.
- 11 Ducos J, Bianchi-Mondain AM, Pageaux G, Conge AM, Poncet R, Vendrell JP, et al: Hepatitis B virus (HBV)-specific in vitro antibody production by peripheral blood mononuclear cells (PBMC) after vaccination by recombinant hepatitis B surface antigen (rHBsAg). *Clin Exp Immunol* 1996;103:15–18.
- 12 Gerlich WH: Diagnostic problems caused by HBsAg mutants: a consensus report of an expert meeting. *Intervirology* 2004;47:310–313.
- 13 De Maddalena C, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L, et al: High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. *Virology* 2007;365:113–124.
- 14 Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, et al: Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. *Trans R Soc Trop Med Hyg* 1997;91:11–14.
- 15 Meldal BH, Moula NM, Barnes IH, Boukef K, Allain JP: A novel hepatitis B virus subgenotype, D7, in Tunisian blood donors. *J Gen Virol* 2009;90:1622–1628.

- 16 Hannachi N, Ben Fredj N, Bahri O, Thibault V, Ferjani A, Gharbi J, et al: Molecular analysis of HBV genotypes and subgenotypes in the Central-East region of Tunisia. *Virol J* 2010;7:302.
- 17 Ciccozzi M, Ciccaglione AR, Lo Presti A, Equestre M, Cella E, Ebranati E, et al: Evolutionary dynamics of HBV-D1 genotype epidemic in Turkey. *J Med Virol* 2014;86:109–116.
- 18 Purdy MA, Talekar G, Swenson P, Araujo A, Fields H: A new algorithm for deduction of hepatitis B surface antigen subtype determinants from the amino acid sequence. *Intervirology* 2007;50:45–51.
- 19 Dindoost P, Jazayeri SM, Karimzadeh H, Saberfar E, Miri SM, Alavian SM: HBsAg variants: common escape issues. *Jundishapur J Microbiol* 2012;5:521–527.
- 20 El Feydi AE, Afifi R, Derdabi O, Cherradi Y, Benazzouz M, et al: Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers. *J Infect* 2011;63:66–75.
- 21 Sayiner AA, Ozcan A, Sengonul A: Naturally occurring MHR variants in Turkish patients infected with hepatitis B virus. *J Med Virol* 2008;80:405–410.
- 22 Khedive A, Norouzi M, Ramezani F, Karimzadeh H, Alavian SM, Malekzadeh R, et al: Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study. *J Viral Hepat* 2013;20:494–501.
- 23 Zehender G, De Maddalena C, Giambelli C, Milazzo L, Schiavini M, Bruno R, et al: Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. *Virology* 2008;380:84–90.
- 24 Zuckerman AJ, Zuckerman JN: Molecular epidemiology of hepatitis B virus mutants. *J Med Virol* 1999;58:193–195.
- 25 Pineiro Y, Leone FG, Pezzano SC, Torres C, Rodríguez CE, Eugenia Garay M, Fainboim HA, et al: Hepatitis B virus genetic diversity in Argentina: dissimilar genotype distribution in two different geographical regions: description of hepatitis B surface antigen variants. *J Clin Virol* 2008;42:381–388.
- 26 Mohebbi SR, Amini-Bavil-Olyae S, Zali N, Noorinayer B, Derakhshan F, Chiani M, et al: Molecular epidemiology of hepatitis B virus in Iran. *Clin Microbiol Infect* 2008;14:858–866.
- 27 Ogura Y, Kurosaki M, Asahina Y, Enomoto N, Marumo F, Sato C: Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. *J Infect Dis* 1999;180:1444–1451.
- 28 Roque-Afonso AM, Férey MP, Ly TD, Graube A, Costa-Faria L, Samuel D, et al: Viral and clinical factors associated with surface gene variants among hepatitis B virus carriers. *Antivir Ther* 2007;12:1255–1263.
- 29 Hsu HY, Chang MH, Ni YH, Chen HL: Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. *Gut* 2004;53:1499–1503.
- 30 Avellon A, Echevarria JM: Frequency of hepatitis B virus 'a' determinant variants in unselected Spanish chronic carriers. *J Med Virol* 2006;78:24–36.
- 31 Song BC, Kim SH, Kim H, Ying YH, Kim HJ, Kim YJ, et al: Prevalence of naturally occurring surface antigen variants of hepatitis B virus in Korean patients infected chronically. *J Med Virol* 2005;76:194–202.
- 32 Shi Y, Wei F, Hu D, Li Q, Smith D, Li N, et al: Mutations in the major hydrophilic region (MHR) of hepatitis B virus genotype C in North China. *J Med Virol* 2012;84:1901–1906.
- 33 Wang XY, Harrison TJ, He X, Chen QY, Li GJ, Liu MH, Li H, Yang JY, Fang ZL: The prevalence of mutations in the major hydrophilic region of the surface antigen of hepatitis B virus varies with subgenotype. *Epidemiol Infect* 2015;143:3572–3582.
- 34 Liu CJ, Kao JH, Shau WY, Chen PJ, Lai MY, Chen DS: Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: correlation with viral serotypes and clinical stages of liver disease. *J Med Virol* 2002;68:50–59.
- 35 Lazarevic I, Cupic M, Delic D, Svrtlih NS, Simonovic J, Jovanovic T: Prevalence of hepatitis B virus MHR mutations and their correlation with genotypes and antiviral therapy in chronically infected patients in Serbia. *J Med Virol* 2010;82:1160–1167.
- 36 Kazim SN, Sarin SK, Sharma BC, Khan LA, Hasnain SE: Characterization of naturally occurring and lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India. *Intervirology* 2006;49:152–160.
- 37 Yeh CT: Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. *Antivir Ther* 2010;15:471–475.
- 38 Sayan M, Cavdar C, Dogan C: Naturally occurring polymerase and surface gene variants of hepatitis B virus in Turkish hemodialysis patients with chronic hepatitis B. *Jpn J Infect Dis* 2012;65:495–501.
- 39 Ding F, Miao XL, Li YX, Dai JF, Yu HG: Mutations in the S gene and in the overlapping reverse transcriptase region in chronic hepatitis B Chinese patients with coexistence of HBsAg and anti-HBs. *Braz J Infect Dis* 2016;20:1–7.
- 40 Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, Azzeh M: Subgenotypes and mutations in the S and polymerase genes of hepatitis B virus carriers in the West Bank, Palestine. *PLoS One* 2014;9:113821.
- 41 Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, et al: The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. *J Clin Microbiol* 2007;45:2971–2978.
- 42 Ireland JH, O'Donnell B, Basuni AA, Kean JD, Wallace LA, Lau GK, et al: Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. *Hepatology* 2000;31:1176–1182.
- 43 Oon CJ, Chen WN: Current aspects of hepatitis B surface antigen mutants in Singapore. *J Viral Hepat* 1998;5:17–23.
- 44 Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, et al: Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. *Hepatology* 1996;24:489–493.
- 45 Veropalumbo E, Marrone A, Vallefuoco L, Perruolo G, Orlando R, Scordino F, et al: Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays. *Intervirology* 2010;53:183–187.
- 46 Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, et al: De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. *Antivir Ther* 2011;16:479–487.
- 47 Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al: Vaccine-induced escape mutant of hepatitis B virus. *Lancet* 1990;336:325–329.
- 48 Mangold CM, Unckell F, Werr M, Streeck RE: Secretion and antigenicity of hepatitis small envelope proteins lacking cysteines in the major antigenic region. *Virology* 1995;211:535–543.
- 49 Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, et al: Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. *J Virol* 1994;68:2671–2676.
- 50 Tong W, Sun L, He J, He S, Du F: A novel nucleotide insertion in S gene of hepatitis B virus in a chronic carrier. *Virol J* 2010;7:104.
- 51 Hou JL, Karayiannis P, Waters J, Luo KX, Liang CS, Thomas HC: A unique insertion in the S gene of surface antigen-negative hepatitis B virus Chinese carriers. *Hepatology* 1995;21:273–278.
- 52 Yu DM, Li XH, Mom V, Lu ZH, Liao XW, Han Y, et al: N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. *J Hepatol* 2014;60:515–522.
- 53 Coleman PF: Surveillance for hepatitis B surface antigen mutants. *J Med Virol* 2006;78:56–58.
- 54 Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R: Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. *Lancet* 1995;345:1406–1407.

- 55 Zhou YH, Zhou JX, Li L, Bi YC, Liu Y, Pan JS, et al: A novel hepatitis B virus mutant coexisting with wild type virus in a carrier with negative HBsAg yet positive HBeAg and anti-HBs. *J Clin Virol* 2009;46:363–366.
- 56 Moradi A, Zhand S, Ghaemi A, Javid N, Tabarraei A: Mutations in the S gene region of hepatitis B virus genotype D in Golestan Province-Iran. *Virus Genes* 2012;44:382–387.
- 57 Coppola N, Onorato L, Minichini C, Di Caprio G, Starace M, Sagnelli C, et al: Clinical significance of hepatitis B surface antigen mutants. *World J Hepatol* 2015;7:2729–2739.
- 58 Pollicino T, Cacciola I, Saffioti F, Raimondo GJ: Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. *Hepatology* 2014;61:408–417.
- 59 Caligiuri P, Cerruti R, Icardi G, Bruzzone B: Overview of hepatitis B virus mutations and their implications in the management of infection. *World J Gastroenterol* 2016;22:145–154.
- 60 Lee SA, Kim K, Kim H, Kim BJ: Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. *J Hepatol* 2012;56:63–69.
- 61 Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT: Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. *Antivir Ther* 2009;14:249–261.
- 62 Huang SF, Chen YT, Lee WC, Chang IC, Chiu YT, Chang Y, et al: Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma. *PLoS One* 2014;9:e89753.
- 63 Zaaier HL, Hemert FJ, Koppelman MH, Lukashov VV: Independent evolution of overlapping polymerase and surface protein genes of hepatitis B virus. *J Gen Virol* 2007;88:2137–2143.
- 64 Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E, et al: Molecular characterization of occult hepatitis B cases in Greek blood donors. *J Med Virol* 2009;81:815–825.
- 65 Pourkarim MR, Sharifi Z, Soleimani A, Amini-Bavil-Olyaei S, Elsadek Fakhr A, Sijmons S, et al: Evolutionary analysis of HBV ‘S’ antigen genetic diversity in Iranian blood donors: a nationwide study. *J Med Virol* 2014;86:144–155.